In papillary thyroid carcinoma <scp>BRAF</scp>^V600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease‐free interval

Abstract

In PTC, BRAF(V600E) induces uPA and uPAR expression. The latter, but not BRAF(V600E) , associates with advanced stages and shorter DFI. If confirmed in larger case studies, they may represent reliable prognostic markers for more accurate risk stratification and postoperative decision-making in patients with PTC.